ACW
Asset Logo

Actinogen Medical Limited

🇦🇺 ASX

🧬 BIOTECHNOLOGY

Compare
Add to watchlist
👑 Overview

📈 Performance

💵 Cost

🤓 Advanced

👨‍👩‍👧‍👦 Community

📈

-4.99%
Annual Growth

5 years average annual growth

💵

$ 500
Minimum Order

Due to regulatory requirements

🌏

14
Pearlers Invested

Since January 2020

👑 Overview

Key information
🔎 Fund Overview

Actinogen Medical Ltd. is a clinical stage Australian biotechnology company, which focuses on the development of novel treatments or cognitive impairment associated with neurological, psychiatric, and metabolic diseases due to raised cortisol. The company is headquartered in Sydney, New South Wales. The company went IPO on 2007-10-16. The firm is engaged in the development of a therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. The firm is engaged in the development of its lead compound, Xanamem, as a therapy for Alzheimer’s Disease, Major Depressive Disorder, Fragile X Syndrome, and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. Xanamem’s mechanism of action is to block the production of cortisol inside cells through the inhibition of the 11B-HSD1 enzyme in the brain. Xanamem is designed to get into the brain after it is absorbed in the intestines upon swallowing its capsule. The company has studied 11B-HSD1 inhibition by Xanamem in approximately 300 volunteers and patients. The firm conducts a series of Phase II studies in multiple diseases to further confirm and characterize Xanamem’s therapeutic potential.

📈 Performance

Price History

-36.22%

1M

1Y

10Y

Graph

Table

Unsure how much or often to invest?
🗓️ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out →
💵 Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out →
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out →

💵 Costs

💵

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

💼

N/A
Management Fee

Included in unit price, not charged by Pearler

💸

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator

🤓 Advanced information

Technical Info

💰 Price*

$0.03

*Price may be up to 24 hours old

👩‍👩‍👦 Community Insights

How our community is investing

🌏 Pearlers invested in ACW

14

📊 Total Capital Earnings

$10K

🔃 Average investment frequency

24 weeks

💵 Average investment amount

$1,266

Last time a customer invested in ACW

10 days
ACW investor breakdown
💵 Income of investors

More than 200k

150k - 200k

18%

100k - 150k

12%

50k - 100k

18%

Less than 50k

47%
👶 Age of investors

18 - 25

29%

26 - 34

21%

35 - 90

50%
🙋 Legal gender of investors

Female

50%

Male

50%

Pearlers who invest in ACW also invest in...

Actinogen Medical Limited

ACWNB

Actinogen Medical Ltd. is a clinical stage Australian biotechnology company, which focuses on the development of novel treatments or cognitive impairment associated with neurological, psychiatric, and metabolic diseases due to raised cortisol. The company is headquartered in Sydney, New South Wales. The company went IPO on 2007-10-16. The firm is engaged in the development of a therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. The firm is engaged in the development of its lead compound, Xanamem, as a therapy for Alzheimer’s Disease, Major Depressive Disorder, Fragile X Syndrome, and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. Xanamem’s mechanism of action is to block the production of cortisol inside cells through the inhibition of the 11B-HSD1 enzyme in the brain. Xanamem is designed to get into the brain after it is absorbed in the intestines upon swallowing its capsule. The company has studied 11B-HSD1 inhibition by Xanamem in approximately 300 volunteers and patients. The firm conducts a series of Phase II studies in multiple diseases to further confirm and characterize Xanamem’s therapeutic potential.

🧬 BIOTECHNOLOGY

Find Out More

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

🙌 Performance (5Yr p.a)

3.34%

📊 Share price

$100.89 AUD

🇦🇺 AUSTRALIA

⛳️ DIVERSIFIED

🧱 MATERIALS

💸 FINANCIALS

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

🙌 Performance (5Yr p.a)

13.93%

📊 Share price

$139.82 AUD

⛳️ DIVERSIFIED

📈 HIGH PRICE GROWTH

🌏 GLOBAL

🤖 TECHNOLOGY

Pilbara Minerals Ltd. engages in the exploration and evaluation of mineral properties. The company is headquartered in Perth, Western Australia and currently employs 917 full-time employees. The company went IPO on 2007-09-19. The firm is primarily engaged in the exploration, development, and mining of minerals in Australia. Its 100% owned Pilgangoora hard-rock lithium operation is located approximately 120 kilometers (kms) from Port Hedland in Western Australia’s resource-rich Pilbara region. The operation consists of two processing plants: the Pilgan Plant, located on the northern side of the Pilgangoora area and produces spodumene and tantalite concentrates, and the Ngungaju Plant is located to the south produces spodumene concentrate. The company owns 70% of the Mt Francisco project, which is located 50 km south-west of the Pilgangoora Project and hosts the large occurrence of outcropping pegmatites located nearby to Port Hedland. The company is also pursuing a proposed downstream joint venture (JV) for the development of an approximately 43,000 tons per annum (tpa) lithium carbonate equivalent (LCE) lithium chemical conversion facility in South Korea.

🙌 Performance (5Yr p.a)

158.06%

📊 Share price

$2.12 AUD

⛏️ MINING

A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.

🙌 Performance (5Yr p.a)

3.86%

📊 Share price

$136.00 AUD

⛳️ DIVERSIFIED

💸 FINANCIALS

🇦🇺 AUSTRALIA

Want more shares? Try these...

📊 Share price

$0.01 AUD

Accent Resources NL engages in the exploration of mineral properties. The company is headquartered in Perth, Western Australia. The company went IPO on 2005-08-26. Its exploration is focused on the discovery and development of iron ore, base metal and precious metal deposits in its project areas in Western Australia. Its projects include Magnetite Range and Norseman. The Magnetite Range project is an advanced iron project, with greenfield gold potential, located approximately 260 kilometers (km) east southeast of Geraldton and immediately adjacent, and along strike of the operating Extension Hill iron ore mine. The Extension Hill project is also referred to as the Mt Gibson project. Magnetite Range project occurs west of the Great Northern Highway between Wubin and Paynes Find and consists of granted mining lease M59/166, granted exploration licenses E59/875 and 1732 and granted PL59/1952. The Norseman project, comprising five mining leases and eight prospecting licenses covering an area of approximately 338 hectares, is located five km south of Norseman in the Dundas Mineral Field.

🙌 Performance (5Yr p.a)

4.00%

📊 Share price

$0.01 AUD

⛏️ MINING

Acumentis Group Ltd. engages in the provision of valuation, research, and advisory services in relation to property and businesses. The company is headquartered in Sydney, New South Wales. The company went IPO on 2003-12-05. The firm provides commercial and residential valuations, research, and property advice to various homeowners, investors, developers, and lenders. The company offers property valuation, insurance valuation, and advisory services to clients, including banks and financial institutions, property developers, property trusts, government, lawyers, accountants, real estate agents and independent retailers. Its services include quantity surveying, acquisition and compensation, capital gains tax, family law and legal, fund forecasts, illicit substance screening, insurance valuation, litigation and legal advisory services, property buyers’ agencies, self-managed super fund (SMSF) property valuation, stamp duty assessments, tax depreciation schedules and tenant representation. The firm serves property classes such as residential, commercial, rural, agribusiness and government portfolios.

🙌 Performance (5Yr p.a)

-9.60%

📊 Share price

$0.08 AUD

🏠 REAL ESTATE

Compare
Add to watchlist